Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 11 to 20 of 545 total matches.
Zilucoplan (Zilbrysq) for Myasthenia Gravis
The Medical Letter on Drugs and Therapeutics • Apr 15, 2024 (Issue 1700)
membrane proteins in the neuromuscular
junction (NMJ).1 Most patients with gMG are treated
initially ...
The FDA has approved the complement C5
inhibitor zilucoplan (Zilbrysq – UCB) for once-daily
subcutaneous treatment of generalized myasthenia
gravis (gMG) in adults who are anti-acetylcholine
receptor (AChR) antibody-positive. Zilucoplan is
the first complement inhibitor to be approved for
treatment of myasthenia gravis that can be self-administered.
Two IV complement inhibitors,
eculizumab (Soliris) and ravulizumab (Ultomiris),
were approved earlier.
Med Lett Drugs Ther. 2024 Apr 15;66(1700):60-2 doi:10.58347/tml.2024.1700c | Show Introduction Hide Introduction
Donislecel (Lantidra) for Type 1 Diabetes
The Medical Letter on Drugs and Therapeutics • Apr 15, 2024 (Issue 1700)
Donislecel (Lantidra) for Type 1 Diabetes ...
The FDA has approved donislecel-jujn (Lantidra –
CellTrans), an allogeneic pancreatic islet
cellular therapy, for use in conjunction with
immunosuppression for treatment of adults with
type 1 diabetes who are unable to approach target
HbA1c because of current repeated episodes of
severe hypoglycemia despite intensive diabetes
management and education. Donislecel is the first
cell-based treatment to be approved in the US for
type 1 diabetes.
Med Lett Drugs Ther. 2024 Apr 15;66(1700):63-4 doi:10.58347/tml.2024.1700d | Show Introduction Hide Introduction
Drugs for Bipolar Disorder
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024 (Issue 1699)
Drugs for Bipolar Disorder
Volume 66 (Issue 1699) April 1, 2024
Bipolar disorder is characterized ...
Bipolar disorder is characterized by episodes of
mania, hypomania, and depression. Recurrences of
manic or (more frequently) depressive symptoms
are common. About 15-20% of patients with bipolar
disorder die by suicide.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):49-54 doi:10.58347/tml.2024.1699a | Show Introduction Hide Introduction
Omalizumab (Xolair) for Food Allergy
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024 (Issue 1699)
, and chronic urticaria,1,2 has now
also been approved for use in conjunction with food
allergen avoidance ...
Omalizumab (Xolair – Genentech), a recombinant
anti-IgE monoclonal antibody FDA-approved for
treatment of allergic asthma, chronic rhinosinusitis
with nasal polyps, and chronic urticaria, has now
also been approved for use in conjunction with food
allergen avoidance to reduce IgE-mediated food
allergic reactions caused by accidental exposure in
patients ≥1 year old. Omalizumab is the first drug to
be approved in the US to reduce allergic reactions to
more than one food. Palforzia, an oral peanut allergen
powder, was approved in 2020 to mitigate allergic
reactions caused by...
Med Lett Drugs Ther. 2024 Apr 1;66(1699):54-6 doi:10.58347/tml.2024.1699b | Show Introduction Hide Introduction
Addendum: Bupropion Safety in Pregnancy
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024 (Issue 1699)
Addendum: Bupropion Safety in Pregnancy
Volume 66 (Issue 1699) April 1, 2024
Our December 11 ...
Our December 11, 2023 article on Drugs for Depression included a single sentence on the safety of bupropion use during
pregnancy: "The safety of bupropion during pregnancy has
not been established; data from a bupropion pregnancy registry
suggested a possible increase in cardiac malformations."
A reader asked us to provide more information.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):56 doi:10.58347/tml.2024.1699c | Show Introduction Hide Introduction
Airsupra: An Inhaled Albuterol/Budesonide Combination for Asthma
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024 (Issue 1698)
hours. They do not decrease airway inflammation.1
Treatment guidelines now recommend that most ...
The FDA has approved Airsupra (AstraZeneca), a
metered-dose inhaler containing the short-acting
beta2-agonist (SABA) albuterol and the inhaled
corticosteroid (ICS) budesonide, for use as needed for
treatment or prevention of bronchoconstriction and to
reduce the risk of exacerbations in patients ≥18 years
old with asthma. Airsupra is the first combination of
a SABA and an ICS to become available in the US. It is
not approved for use as maintenance therapy.
Med Lett Drugs Ther. 2024 Mar 18;66(1698):41-3 doi:10.58347/tml.2024.1698a | Show Introduction Hide Introduction
Penbraya: A Pentavalent Meningococcal Vaccine
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024 (Issue 1698)
, and Y (MenACWY; Menveo, MenQuadfi)1 and
two meningococcal serogroup B vaccines (MenB;
Bexsero ...
The FDA has licensed Penbraya (Pfizer), a pentavalent
polysaccharide conjugate meningococcal
vaccine, for prevention of invasive meningococcal
disease caused by Neisseria meningitidis
serogroups A, B, C, W, or Y (MenABCWY) in persons
10-25 years old. Penbraya is the only meningococcal
vaccine that contains all five of these serogroups.
Two quadrivalent polysaccharide conjugate
meningococcal vaccines containing serogroups A,
C, W, and Y (MenACWY; Menveo, MenQuadfi) and
two meningococcal serogroup B vaccines (MenB;
Bexsero, Trumenba) are available in the US (see
Table...
Med Lett Drugs Ther. 2024 Mar 18;66(1698):43-5 doi:10.58347/tml.2024.1698b | Show Introduction Hide Introduction
Mirikizumab (Omvoh) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024 (Issue 1698)
with a biologic drug, but the risk of
lymphoma is a concern.1-5
PHARMACOLOGY — IL-23 is a proinflammatory ...
The FDA has approved the interleukin (IL)-23
antagonist mirikizumab-mrkz (Omvoh – Lilly) for
treatment of moderately to severely active ulcerative
colitis (UC) in adults. Mirikizumab is the first selective
IL-23 antagonist to be approved for this indication.
Ustekinumab (Stelara), an IL-12/23 antagonist, was
approved for treatment of UC in 2019. The IL-23
antagonist risankizumab (Skyrizi) is approved for
treatment of Crohn's disease.
Med Lett Drugs Ther. 2024 Mar 18;66(1698):46-7 doi:10.58347/tml.2024.1698c | Show Introduction Hide Introduction
In Brief: A New OTC Naloxone Nasal Spray (RiVive)
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024 (Issue 1698)
) product for emergency
treatment of opioid overdose.1 Two 4-mg naloxone
nasal spray formulations, Narcan ...
The FDA has approved RiVive (Harm Reduction
Therapeutics), a 3-mg naloxone nasal spray, as
an over-the-counter (OTC) product for emergency
treatment of opioid overdose. Two 4-mg naloxone
nasal spray formulations, Narcan and one of its
generics, were approved for OTC sale in 2023.
Med Lett Drugs Ther. 2024 Mar 18;66(1698):47-8 doi:10.58347/tml.2024.1698d | Show Introduction Hide Introduction
Drugs for Menopausal Symptoms
The Medical Letter on Drugs and Therapeutics • Mar 04, 2024 (Issue 1697)
is the most effective treatment for GSM.1 When OTC
nonhormonal products are ineffective, low-dose
vaginal ...
The primary symptoms of menopause are genitourinary
and vasomotor. The genitourinary syndrome
of menopause (GSM) includes symptoms such as
burning, irritation, dryness, dyspareunia, dysuria,
and recurrent urinary tract infection. Vasomotor
symptoms (VMS; hot flashes, night sweats) often
disrupt sleep.
Med Lett Drugs Ther. 2024 Mar 4;66(1697):33-8 doi:10.58347/tml.2024.1697a | Show Introduction Hide Introduction